You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 9, September 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Evidence-Based Dermatology: Critically Appraised Topic
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Dermatologic Disorders
 •Acne
 •Pediatrics
 •Neonatology and Infant Care
 •Women's Health
 •Pregnancy and Breast Feeding
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

What Is the Chance of a Normal Pregnancy in a Woman Whose Fetus Has Been Exposed to Isotretinoin?

Michael J. Sladden, MAE, MRCP(UK); Karen E. Harman, MD, MRCP

Arch Dermatol. 2007;143(9):1187-1188.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Clinical Question

Recently, one of our patients who was taking isotretinoin became pregnant. This occurred despite appropriate counseling, a negative pregnancy test result before commencing treatment, and use of the combined oral contraceptive pill Microgynon 30 (Schering Health Care, West Sussex, England) (levonorgestrel, 150 µg, ethinylestradiol, 30 µg). The patient did not want to terminate her pregnancy. The aim of this Critically Appraised Topic is to explore the literature to determine the chance of delivering a healthy child after fetal exposure to isotretinoin; the types of fetal malformations associated with it; and what monitoring should be performed.


Background

Since introduction of the drug in 1982, over 2000 pregnancies in the United States have been affected by fetal exposure to isotretinoin,1 most resulting in spontaneous or elective abortions.2-6


Literature Search

We searched the Medline and EmBase databases from 1966 to March 2007 using the terms isotretinoin . . . [Full Text of this Article]

Appraisal of the Evidence

Limitations

Clinical Bottom Line

What Happened to Our Patient?

AUTHOR INFORMATION

Department of Medicine, University of Tasmania, Launceston, Australia (Dr Sladden), and Department of Dermatology, Leicester Royal Infirmary, Leicester, England (Dr Harman)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Accessible Evidence-Based Medicine: Critically Appraised Topics
David A. Barzilai and Martin A. Weinstock
Arch Dermatol. 2007;143(9):1189-1190.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.